logo
logo

Ranok Therapeutics Secures $40 Million Series B Financing To Advance Its Innovative Targeted Protein Degradation Pipeline

Aug 18, 2021•almost 4 years ago

Amount Raised

$40 Million

Round Type

series b

BostonHealth CareCommerce And Shopping

Description

Ranok Therapeutics (Hangzhou) Co. Ltd., an emerging biopharmaceutical company focused on developing breakthrough therapies for cancer and other serious diseases, today announced it had secured a $40 million Series B funding round denominated in both U.S. dollars and Chinese yuan. The financing was led by Lapam Capital and Shanghai Healthcare Capital, with additional participation from Wu Capital, Zhongguancun Kaiyuan Capital and existing investors, and representatives of the new investors will join Ranok’s expanded board of directors

Company Information

Company

Ranok Therapeutics

Location

Boston, Massachusetts, United States

About

Ranok is a privately held, emerging biopharmaceutical company that is pioneering its proprietary CHAMP platform technology, an innovative approach to targeted protein degradation (TPD) for the discovery and development of novel therapeutics. Ranok was founded by a leadership team composed of industry veterans from both Chinese and American biotech and pharmaceutical companies and is based in two of the world’s leading centers of innovation and medical research: Hangzhou China and Greater Boston Massachusetts USA. By bringing together cutting-edge medical research from both China and the United States, Ranok’s goal is to create transformative medicines to benefit patients suffering from cancer and other serious diseases around the world. For more information, please visit the company website at www.ranoktherapeutics.com or follow us at LinkedIn and on Twitter @RanokTx.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech